Publications by authors named "P Bie"

Objective: Serum prolactin measurements are important in the differential diagnosis of pituitary masses and subfertility. We observed discrepancies in serum prolactin levels in several patients measured with different immunoassays. Despite differences in assay results, the reference intervals (RIs) derived by the manufacturers were similar.

View Article and Find Full Text PDF

Hormones are specific molecules measured in biological fluids by elaborate analytical systems requiring meticulous attention. Variation between laboratories can be expected. However, recently published measurements of AVP, OXT, and BNP in human plasma under basal/control conditions include numbers which, between publications, vary by 100-10 000-fold.

View Article and Find Full Text PDF

The use of exogenous glucocorticoids is a common cause of Cushing syndrome. We present a case of exogenous Cushing syndrome caused by Binahong: an over-the-counter 'herbal' supplement. A 54-year-old woman presented with weight gain, joint pain, hypertension and poorly regulated type 2 diabetes mellitus despite the start of semaglutide one year before presentation.

View Article and Find Full Text PDF

Background: Lycium barbarum polysaccharide (LBP) is an active ingredient extracted from Lycium barbarum that inhibits neuroinflammation, and Lycium barbarum glycopeptide (LbGp) is a glycoprotein with immunological activity that was purified and isolated from LBP. Previous studies have shown that LbGp can regulate the immune microenvironment, but its specific mechanism of action remains unclear.

Aims: In this study, we aimed to explore the mechanism of action of LbGp in the treatment of spinal cord injury through metabolomics and molecular experiments.

View Article and Find Full Text PDF
Article Synopsis
  • Primary liver cancer is a major health concern in China, with hepatocellular carcinoma accounting for 75-85% of cases, ranking as the fourth most common cancer and the second leading cause of cancer-related deaths in the country.
  • The Guidelines for Diagnosis and Treatment of Primary Liver Cancer were first published in 2017 and have been updated due to new research and evidence in the field, leading to the 2022 Edition written by over 100 experts.
  • The updated guidelines aim to promote evidence-based practices to enhance the 5-year survival rate of liver cancer patients in alignment with the "Health China 2030 Blueprint."
View Article and Find Full Text PDF